Literature DB >> 18449524

[Proof of botulinum toxin antibodies with the Extensor Digitorum Brevis Test].

A Bachhuber1, A Wagner, G Reichel, M Doberenz, A Stenner, W Hermann.   

Abstract

INTRODUCTION: Some patients treated with botulinum toxin (btx) develop neutralizing btx antibodies (btx-ab). The expensive Mouse Diaphragm Bioassay (MDB) is considered as the gold standard by many authors. We wanted to examine whether the Extensor Digitorum Brevis Test (EDB test) is a reliable method to test for btx-ab.
METHOD: We performed an electroneurography of the m. extensor digitorum brevis on both feet of 23 patients with known MDB. Afterwards the right feet were injected with 25 U of btx, and 21-28 days later the electroneurography was performed on both sides again. Finally we correlated the measured values (muscular wave latency, amplitude, area, and duration) intraindividually and with the MDB results.
RESULTS: The parameters area and amplitude correlated highly significantly with the MDB (P<0.001 for both tests). Decreasing the amplitude to at least 65% of its initial value indicated the presence of btx-ab. In that way 22 of 23 EDB classifications were identical to those of the MDB, yielding a sensitivity of 92.86% and a specificity of 100%.
CONCLUSION: The EDB test is a reliable technique for detecting btx-ab with high sensitivity and specificity. The EDB test can replace the MDB.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18449524     DOI: 10.1007/s00115-008-2470-x

Source DB:  PubMed          Journal:  Nervenarzt        ISSN: 0028-2804            Impact factor:   1.214


  15 in total

1.  Comparison of mouse bioassay and immunoprecipitation assay for botulinum toxin antibodies.

Authors:  P A Hanna; J Jankovic; A Vincent
Journal:  J Neurol Neurosurg Psychiatry       Date:  1999-05       Impact factor: 10.154

2.  Botulinum toxin antibody testing: comparison between the immunoprecipitation assay and the mouse diaphragm assay.

Authors:  D Dressler; G Dirnberger
Journal:  Eur Neurol       Date:  2001       Impact factor: 1.710

3.  Botulinum toxin antibody testing: comparison between the mouse protection assay and the mouse lethality assay.

Authors:  D Dressler; G Dirnberger; K P Bhatia; A Irmer; N P Quinn; H Bigalke; C D Marsden
Journal:  Mov Disord       Date:  2000-09       Impact factor: 10.338

4.  Extensor digitorum brevis test and resistance to botulinum toxin type A.

Authors:  Paul H Gordon; Clifton L Gooch; Paul E Greene
Journal:  Muscle Nerve       Date:  2002-12       Impact factor: 3.217

5.  Botulinum A toxin therapy: neutralizing and nonneutralizing antibodies--therapeutic consequences.

Authors:  H Göschel; K Wohlfarth; J Frevert; R Dengler; H Bigalke
Journal:  Exp Neurol       Date:  1997-09       Impact factor: 5.330

6.  Safety and efficacy of NeuroBloc (botulinum toxin type B) in type A-resistant cervical dystonia.

Authors:  M F Brin; M F Lew; C H Adler; C L Comella; S A Factor; J Jankovic; C O'Brien; J J Murray; J D Wallace; A Willmer-Hulme; M Koller
Journal:  Neurology       Date:  1999-10-22       Impact factor: 9.910

Review 7.  Botulinum toxin injection of eye muscles to correct strabismus.

Authors:  A B Scott
Journal:  Trans Am Ophthalmol Soc       Date:  1981

8.  The sternocleidomastoid test: an in vivo assay to investigate botulinum toxin antibody formation in humans.

Authors:  D Dressler; H Bigalke; J C Rothwell
Journal:  J Neurol       Date:  2000-08       Impact factor: 4.849

9.  Use of botulinum toxin type F injections to treat torticollis in patients with immunity to botulinum toxin type A.

Authors:  P E Greene; S Fahn
Journal:  Mov Disord       Date:  1993-10       Impact factor: 10.338

10.  Botulinum antibodies in dystonic patients treated with type A botulinum toxin: frequency and significance.

Authors:  M Zuber; M Sebald; N Bathien; J de Recondo; P Rondot
Journal:  Neurology       Date:  1993-09       Impact factor: 9.910

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.